<DOC>
	<DOCNO>NCT00075816</DOCNO>
	<brief_summary>The study design Phase III , randomize , open label , multicenter , prospective , comparative trial granulocyte colony stimulate factor ( G-CSF ) -mobilized peripheral blood stem cell ( PBSC ) versus marrow unrelated donor transplantation patient hematologic malignancy . Recipients stratify transplant center disease risk randomize either PBSC marrow arm 1:1 ratio .</brief_summary>
	<brief_title>Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant Individuals With Hematologic Cancers ( BMT CTN 0201 )</brief_title>
	<detailed_description>BACKGROUND : Many study allogeneic marrow transplantation show high dose marrow cell correlate robust hematopoietic engraftment low mortality infectious complication . Peripheral blood stem cell ( PBSC ) collect mobilization granulocyte colony stimulate factor ( G-CSF ) contain large number CD34-positive ( CD34 ) progenitor total cell bone marrow . These observation lead hypothesis transplantation PBSC would lead low mortality compare transplantation marrow . In addition , PBSC graft high T cell content , predict possibly powerful anti-leukemia effect . However , high T cell content PBSC may also lead increase incidence severity acute chronic graft-versus-host disease ( GVHD ) . This concern especially serious donor unrelated recipient . This prospective , randomize , multicenter clinical trial unrelated donor transplantation test hypothesis transplantation PBSC lead similar patient survival compare transplantation marrow . DESIGN NARRATIVE : This Phase III randomize , open label , multicenter clinical trial sponsor National Marrow Donor Program ( NMDP ) National Institutes Health ( NIH ) . The objective trial test null hypothesis difference overall survival PBSC versus marrow transplant HLA compatible unrelated donor . The study compare G-CSF-mobilized PBSC transplantation bone marrow transplantation HLA-compatible unrelated donor patient leukemia , myelodysplastic myeloproliferative syndrome . Conditioning GVHD prophylaxis regimen vary center within center , however , center must declare randomization regimen use patient . The primary endpoint trial 2-year survival follow randomization . Secondary analysis consider neutrophil platelet recovery , acute chronic GVHD , time immunosuppressive therapy , relapse , infection , adverse event immune reconstitution . The trial include evaluation patient donor quality life , composition graft , immune reconstitution . Accrual anticipate 3 year follow-up period 3 year .</detailed_description>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<criteria>Patient One follow diagnosis : Acute myelogenous leukemia follow stage : first remission , second remission , third subsequent remission , remission Acute lymphoblastic leukemia follow stage : first remission , second remission , third subsequent remission , remission Chronic myelogenous leukemia follow stage : chronic phase , accelerated phase , blast phase Myelodysplastic syndrome ( MDS ) follow stage : refractory anemia ; refractory anemia ring sideroblast ; refractory cytopenia multilineage dysplasia ; refractory cytopenia multilineage dysplasia ring sideroblast ; refractory anemia excess blasts1 ( 510 % blast ) ; refractory anemia excess blasts2 ( 1020 % blast ) ; myelodysplastic syndrome , unclassified ; MDS associate isolated del ( 5q ) Myeloproliferative disease : chronic myelomonocytic leukemia ; agnogenic myeloid metaplasia myelofibrosis ( idiopathic myelofibrosis ) ; juvenile myelomonocytic leukemia Therapyrelated acute myelogenous leukemia ( AML ) MDS prior malignancy remission least 12 month . If remission le 12 month , Medical Monitor Protocol Chair approval require eligibility Patient Prior allogeneic autologous transplant use hematopoietic stem cell source ; patient secondary malignancy prior autologous transplant eligible ; prior autologous transplant must perform primary malignancy ( lymphoma ) must occur 12 month prior enrollment Lymphoma ( 11 % 2001 NMDP transplant ) , malignant disorder ( 6 % ) , nonmalignant disorder ( 9 % ) Donor Matched HLAA , B , DRB1 antigens 1 . One antigen mismatch HLAA , B , DRB1 acceptable without mismatch HLAC 2 . Typing DNA technique : intermediate resolution A , B , C , high resolution DRB1 . HLAC type mandatory count match . Willing undergo bone marrow harvest GCSF administration apheresis Willing randomly assign either marrow PBSC collection Adequate peripheral venous access leukapheresis willing undergo placement central catheter Donor center affiliation NMDP Additional donor inclusion criterion find Donor Companion Manual Donor Pregnant ( positive serum Î²HCG ) uninterruptible breastfeed Known allergy GCSF E. Coliderived recombinant protein product History autoimmune disorder History deep vein thrombosis venous thromboembolism History iritis episcleritis History serious adverse reaction anesthesia Thrombocytopenia ( platelet le 150,000 per mcL ) baseline evaluation Current treatment lithium Presence sickle hemoglobin demonstrate appropriate test hemoglobin electrophoresis Receiving experimental therapy investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>